FFinance

Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says

  • bytady
  • January 22, 2025
  • 1 minute read
Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says
0
Shares
0
0
0
0

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images

0 Shares:
Share 0
Tweet 0
Pin it 0

Leave a Reply

Your email address will not be published. Required fields are marked *

— Previous article

Best Protein Powders in 2025

Next article —

Donald Trump pardons Silk Road creator Ross Ulbricht

You May Also Like
Why Tesla Stock Surged Today
Read More
  • 2 minute read
FFinance

Why Tesla Stock Surged Today

  • bytady
  • January 18, 2025
Tesla (TSLA 3.06%) stock saw significant gains Friday thanks to multiple catalysts. The company’s share price closed out…